COMMUNIQUÉS West-GlobeNewswire

Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study
31/07/2018
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by persons with diabetes and pre-diabetics today announced [...]
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2018 Financial and Operating Results
31/07/2018
BOTHELL, Wash., July 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Kane Biotech and the U.S. Army Institute of Surgical Research Sign Extension of Cooperative Research and Development Agreement
31/07/2018
WINNIPEG, Manitoba, July 31, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce a three year Cooperative Research and Development Agreement [...]
Nu-Med Plus, Inc. Approaches Landmark Certification to Speed New Nitric Oxide Medical Device Approval
31/07/2018
Innovative Nitric Oxide Delivery Device Company Announces Program to Attain ISO 13485 Certification SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device leader developing [...]
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer
31/07/2018
Experienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart® WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- [...]
aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer
31/07/2018
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Aptose to Present at the 2018 Global Congress on Oncology and Cancer
31/07/2018
SAN DIEGO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of [...]
PolarityTE, Inc. Announces Alain Adam as Vice President of Sales
31/07/2018
SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL) today announced the appointment of Alain Adam as Vice President of Sales. Mr. Adam will lead the company’s continued development of its [...]
Summary of Calendar for Upcoming Proposed Delcath Rights Offering
31/07/2018
The Company’s Directors and Officers Indicate Intent to Participate in the Rights Offering Once Effective NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology [...]
Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
31/07/2018
Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program Program aims to counteract antibiotic resistance by use of artificial intelligence in drug development Amsterdam, the Netherlands, [...]
Active Biotech provides update on laquinimod in Huntington's disease
31/07/2018
PRESS RELEASE Lund Sweden, July 31, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical Industries Ltd. The Phase 2 LEGATO-HD [...]
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period
31/07/2018
PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period TiGenix becomes a wholly owned subsidiary of Takeda Ordinary Shares have been delisted from Euronext Brussels The [...]
Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait
31/07/2018
COMMUNIQUÉ DE PRESSE Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait TiGenix devient donc une filiale propriété exclusive de Takeda Les Actions ordinaires ont été radiées d' [...]
Sanofi: Q2 2018 Performance Positions Sanofi for New Growth Phase
31/07/2018
Paris, July 31, 2018 Q2 2018 Performance Positions Sanofi for New Growth Phase Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.7% +0.1% €16,074m -7.2% -0.1% IFRS net income [...]
Sanofi : Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance
31/07/2018
Paris, le 31 juillet 2018 Après les résultats du T2 2018, Sanofi bien placé pour une nouvelle période de croissance T2 2018 Variation Variation à TCC S1 2018 Variation Variation à TCC Chiffre d'affaires net IFRS publié [...]
Zealand announces an 85% increase in Soliqua® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018
31/07/2018
Company announcement - No. 19/2018 Zealand announces an 85% increase in Soliqua ® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018 Net sales of Soliqua ® 100/33/ Suliqua® and Lyxumia®/Adlyxin® of [...]
Eckert & Ziegler BEBIG: First Half-Year Results 2018 Published
31/07/2018
Seneffe - Belgium, July 31, 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its half-year results 2018. The report including a selection of consolidated key [...]
Eckert & Ziegler BEBIG: Publication du résultat du premier semestre 2018
31/07/2018
Seneffe - Belgique, 31 juillet 2018, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) a communiqué aujourd'hui son rapport du 1er semestre 2018. Le rapport qui comprend une sélection de [...]
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
31/07/2018
Geneva, Switzerland and Boston, MA - July 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]

Pages